Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.

ABSTRACT:

Background/aims

Direct-acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug interactions (DDIs) with DAAs might limit clinical practice in this special population.

Methods

The number, class, and characteristics of comedications and their potential DDIs with five DAA regimens were analyzed among HCV-viremic patients from 23 hemodialysis centers in Taiwan.

Results

Of 2,015 hemodialysis patients screened in 2019, 169 patients seropositive for HCV RNA were enrolled (mean age, 65.6 years; median duration of hemodialysis, 5.8 years). All patients received at least one comedication (median number, 6; mean clas

SUBMITTER: Hsu PY 

PROVIDER: S-EPMC7820195 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature